Form 4: SpringWorks Therapeutics Executive Herschel Weinstein Receives Stock and Option Grants
SEC Form 4 Filing
Herschel Weinstein, General Counsel & Secretary of SpringWorks Therapeutics, received grants of restricted stock units and stock options on January 10, 2025.
Summary
- Herschel S. Weinstein, General Counsel & Secretary of SpringWorks Therapeutics, Inc., filed a Form 4 on January 14, 2025, reporting changes in beneficial ownership.
- On January 10, 2025, Weinstein was granted 12,126 restricted stock units (RSUs) and an option to purchase 35,431 shares of common stock.
- The RSUs vest in three tranches: 33% on January 10, 2026, 33% on January 10, 2027, and 34% on January 10, 2028, contingent upon continued service.
- The stock options vest in 48 equal monthly installments starting January 10, 2025, also subject to continued service, and expire on January 10, 2035.
- Following these transactions, Weinstein beneficially owns 55,239 shares of SpringWorks Therapeutics common stock and options to purchase 35,431 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contributions.
Positives
- The grant of RSUs and stock options aligns Weinstein's interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to SpringWorks Therapeutics.
Risks
- The value of the RSUs and stock options is dependent on the future performance of SpringWorks Therapeutics' stock.
- Weinstein must remain employed by the company to fully vest in the RSUs and stock options.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of continued contributions from the reporting person.
Industry Context
Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The vesting schedules are designed to align management's interests with long-term shareholder value.
Comparison to Industry Standards
- Equity compensation practices vary across the pharmaceutical industry, but grants of RSUs and stock options are typical for executive-level employees.
- Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans to incentivize their leadership teams.
- The specific terms of the grants, such as vesting schedules and option exercise prices, are tailored to the individual company's circumstances and performance goals.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of RSU and stock option grants. |
| 01/10/2026 | First vesting date for 33% of the RSUs. |
| 01/10/2027 | Second vesting date for 33% of the RSUs. |
| 01/10/2028 | Final vesting date for 34% of the RSUs. |
| 01/10/2035 | Expiration date of the stock options. |
| 01/14/2025 | Date Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.